[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590023":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":20,"studyPopulation":24,"armGroups":25,"interventions":36,"overallOfficials":45,"centralContacts":49,"locations":55,"responsibleParty":73,"collaborators":20,"id":76,"slug":20,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":20,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":20,"studyType":88,"phases":20,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":57,"whyStopped":20,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Xijing Hospital of Digestive Diseases","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Clinical remission rates and endoscopic remission rates at 14 weeks, 30 weeks, 52 weeks, and 2 years after first-line biologics treatment","Evaluate the clinical remission rate and endoscopic remission rate of first-line biologics treatment at 14 weeks, 30 weeks, 52 weeks, and 2 years based on the Mayo scoring system and endoscopic examination results","From enrollment to the end of treatment at 2 years.",[14,17],{"measure":15,"description":16,"timeFrame":12},"Clinical response rate, endoscopic response rate, and hormone free response rate at 14 weeks, 30 weeks, 52 weeks, and 2 years after first-line biologics treatment","Evaluate the clinical response rate, endoscopic response rate, and hormone free response rate at 14 weeks, 30 weeks, 52 weeks, and 2 years after first-line biologic therapy based on the Mayo scoring system and endoscopic examination results",{"measure":18,"description":19,"timeFrame":12},"Factors affecting the efficacy of two biological agents in the treatment process","After balancing confounding factors through PSM, IPTW, and other methods, the factors affecting the efficacy of biologics were analyzed through survival analysis curves",null,{"allocation":20,"interventionModel":20,"interventionModelDescription":20,"primaryPurpose":20,"observationalModel":22,"timePerspective":23,"maskingInfo":20},"CASE_CONTROL","PROSPECTIVE","Moderate to severe UC patients treated with biological agents in the Xijing Hospital of Digestive Diseases",[26,31],{"label":27,"type":20,"description":28,"interventionNames":29},"The IFX group","The first-line use of IFX group regularly uses IFX treatment for 3 cycles before continuing to use IFX or adjusting to VDZ treatment.",[30],"Drug: first-line biologic：IFX",{"label":32,"type":20,"description":33,"interventionNames":34},"The VDZ group","The first-line use of VDZ group regularly uses VDZ treatment for 3 cycles before continuing to use VDZ or adjusting to IFX treatment.",[35],"Drug: first-line biologic:VDZ",[37,42],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":20},"DRUG","first-line biologic：IFX","IFX is administered intravenously at a dose of 5-10mg\u002Fkg, once at weeks 0, 2, and 6 (or 0, 1, and 5), and then every 8 weeks at a dose of 5mg\u002Fkg for maintenance treatment. VDZ is administered intravenously at a dose of 300mg\u002Ftime, once at weeks 0, 2, and 6, and then every 8 weeks at a dose of 300mg for maintenance treatment.",[27],{"type":38,"name":43,"description":40,"armGroupLabels":44,"otherNames":20},"first-line biologic:VDZ",[32],[46],{"name":47,"affiliation":5,"role":48},"Min Chen","STUDY_DIRECTOR",[50],{"name":51,"role":52,"phone":53,"phoneExt":20,"email":54},"Dongdong He","CONTACT","0086 + 02984771535","929731975@qq.com",[56],{"facility":5,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"RECRUITING","Shanxi","Xi'an","710032","China","CN",{"type":64,"coordinates":65},"Point",[66,67],120.0505,27.66628,{"lat":67,"lon":66},[70],{"name":71,"role":52,"phone":53,"phoneExt":20,"email":72},"Yongquan Shi","shiyquan@fmmu.edu.cn",{"type":74,"investigatorFullName":71,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Clinical Professor","100590023",false,"NCT06962020","Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis","Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis: A Prospective, Multi-Center, Real-World Study","Inclusion Criteria:\n\n* Age range of 18-70 years old, gender not limited;\n* According to international guidelines and consensus, patients with ulcerative colitis should be diagnosed to exclude radiation enteritis, infectious enteritis, tumor related diseases, etc;\n* Patients assessed as moderate to severe ulcerative colitis based on the Mayo score;\n* During the follow-up period, no relevant treatments (drugs and surgery) were used that could affect the assessment of the efficacy of biologics\n\nExclusion Criteria:\n\n* Patients with hemodynamic instability;\n* Patients with obvious liver and kidney function injury: bilirubin, aminotransferase (ALT, AST) exceeded the upper limit of normal by 2 times; eGFR\\\u003C60ml\u002Fmin or dialysis patients;\n* Patients allergic to IFX or VDZ;\n* Patients whose primary disease was gastrointestinal malignancy;\n* Patients currently suffering from serious or uncontrolled underlying diseases of the blood, digestive tract, metabolism, endocrine, lung, heart, nervous system, mental system, etc.;\n* Female patients during pregnancy and breastfeeding (including patients with reproductive needs);\n* Patients with current infection with infectious diseases (hepatitis B, hepatitis C, syphilis, AIDS, tuberculosis, etc.);\n* Patients who cannot cooperate with regular follow-up and review of laboratory indicators;\n* Any other circumstances which, in the opinion of the investigator, would render the subject unfit for study inclusion.","ALL","18 Years","70 Years",{"count":86,"type":87},400,"ESTIMATED","OBSERVATIONAL","The purpose of this prospective, multicenter, real-world study is to compare the efficacy differences and influencing factors of different first-line biologics in patients with moderate to severe ulcerative colitis. The question that this study aims to answer is: When treating patients with moderate to severe ulcerative colitis, should IFX or VDZ be prioritized as the first-line choice for biologics?, Which biological agent has better therapeutic effect?. Researchers will observe and follow up with patients with moderate to severe ulcerative colitis treated with different biologics on the front line, evaluate their condition changes, eliminate relevant interfering factors, and draw the final conclusion.",[91],"Ulcerative Colitis (UC)",[93,94],"biologics","ulcerative colitis","2025-07-01",{"date":97,"type":98},"2025-07-03","ACTUAL",{"date":100,"type":98},"2025-04-30",{"date":102,"type":87},"2025-11-20",{"name":5,"class":6},1]